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Abstract
Background: Chronic inflammation promotes atherosclerosis in cardiovascular disease and is a major prognostic factor for
patients undergoing percutaneous coronary intervention (PCI). Macrophage migration inhibitory factor (MIF) is involved in
the progress of atherosclerosis and plaque destabilization and plays a pivotal role in the development of acute coronary
syndromes (ACS). Little is known to date about the clinical impact of MIF in patients with symptomatic coronary artery
disease (CAD).
Methods and Results: In a pilot study, 286 patients with symptomatic CAD (n=119 ACS, n=167 stable CAD) undergoing
PCI were consecutively evaluated. 25 healthy volunteers served as control. Expression of MIF was consecutively measured in
patients at the time of PCI. Baseline levels of interleukin 6 (IL-6), ‘‘regulated upon activation, normal T-cell expressed, and
secreted’’ (RANTES) and monocyte chemoattractant protein-1 (MCP-1) were measured by Bio-Plex Cytokine assay. C-reactive
protein (CRP) was determined by Immunoassay. Patients with ACS showed higher plasma levels of MIF compared to
patients with stable CAD and control subjects (median 2.85 ng/mL, interquartile range (IQR) 3.52 versus median 1.22 ng/mL,
IQR 2.99, versus median 0.1, IQR 0.09, p,0.001). Increased MIF levels were associated with CRP and IL-6 levels and correlated
with troponin I (TnI) release (spearman rank coefficient: 0.31, p,0.001). Patients with ACS due to plaque rupture showed
significantly higher plasma levels of MIF than patients with flow limiting stenotic lesions (p=0.002).
Conclusion: To our knowledge this is the first study, demonstrating enhanced expression of MIF in ACS. It is associated with
established inflammatory markers, correlates with the extent of cardiac necrosis marker release after PCI and is significantly
increased in ACS patients with ‘‘culprit’’ lesions. Further attempts should be undertaken to characterize the role of MIF for
risk assessment in the setting of ACS.
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Introduction
Atherosclerosis is driven by sustained inflammation leading to
chronic alterations of inflammatory mediators, like CRP, pro-
inflammatory cytokines, metalloproteinases (MMPs), adhesion
molecules and selectins [1,2]. The interaction of endothelial cells,
monocytes, macrophages and platelets plays a crucial role in
upholding a pro-inflammatory and prothrombotic milieu leading
to plaque instability and subsequent atherothrombotic events [3].
Additionally, there have been in-vitro data supporting the linkage of
platelet activation, hyperaggregability and up-regulation of cyto-
kines and chemokines involved in recruitment of inflammatory
cells [4]. ACS are triggered by inflammatory response and plaque
degradation as indicated by increased inflammatory processes at
site of intimal rupture and increased circulating levels of MMPs
during the event [5,6]. MIF is an integral component of the host
antimicrobial alarm system and stress response that promotes the
pro-inflammatory functions of immune cells. A growing body of
literature suggests that MIF is involved in pathomechanisms of
sepsis, inflammatory and autoimmune diseases and atherosclerosis
[7–9]. Additionally, MIF has previously been reported to be
associated with signs of plaquae instability [10]. Hence, MIF might
be a potential biomarker to predict the severity and the risk of
ACS and to suggest therapies that target MIF pathways as
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38376attractive treatment options for cardiovascular diseases. To date
little is known about the clinical impact of MIF in CAD. Hence,
the aim of the present study was to further evaluate the association
of MIF in a consecutive population of patients with CAD and its
association with established inflammatory markers, angiographic
findings and its shortterm prognostic impact.
Materials and Methods
Study Population and Data Acquisition
A consecutive pilot study was performed in 286 unselected
patients recruited at the University Hospital Tu ¨bingen to evaluate
the association of MIF, inflammatory markers and platelet
function under antiplatelet therapy. All patients underwent
coronary stent implantation (bare-metal and drug-eluting stents)
due to symptomatic CAD. Platelet function analysis was
performed in all subjects before and after receiving a 600-mg
clopidogrel loading dose in addition to aspirin (ASA) pre-
treatment. The study protocol was approved by the local ethical
committee. Inclusion criteria comprised written informed consent
and an age .18 years. A standard maintenance dose of 75 mg/
day Clopidogrel + ASA 100 mg/day was prescribed for all
patients in the further course. ACS was diagnosed in the presence
of one of the following criteria: unstable angina (clinical symptoms
and new ECG changes, but no markers of myocardial necrosis),
acute myocardial infarction with markers of myocardial necrosis
(TnI or creatine kinase (CK)) including ST-elevation myocardial
infarction (STEMI) and non–ST-elevation myocardial infarction
(NSTEMI).
Biochemical Measurements
Peripheral venous blood samples were obtained in EDTA
collection tubes at the time of PCI, centrifuged at room
temperature (15006g) for 15 min, and stored as EDTA-plasma
at 280uC, until MIF levels and inflammatory markers were
analysed. To assess MIF concentrations in the obtained plasma
samples we used anti-human MIF ELISA, R&D Systems, Inc.,
Minneapolis, USA. The assay was performed according to the
instruction booklet provided by R&D systems, Inc.
IL-6, MCP-1 and RANTES were determined using the Bio-
Plex
 cytokine assay (Bio-Rad Laboratories Inc., Hercules, CA,
USA) according to manufacturer’s instructions. Samples were
tested for CRP using an immunoturbidimetric assay (ADVIA 1800
chemistry analyzer, Siemens Medical Solutions, Germany).
Angiographic Analysis
Coronary angiography was performed in all patients. All
angiograms were analyzed by two independent blinded investiga-
tors. Plaque rupture was angiographically defined by thrombus
containing ‘‘culprit’’ lesion without significant angiographic
stenosis.
Statistical Analysis
A chi-square test was performed to evaluate the distribution of
categorical data and a Fisher’s exact test for dichotomous analysis.
A Shapiro-Wilk test was used to assess for normality of continuous
variables. Normally distributed continuous data are expressed as
mean 6 standard deviation. For these variables means between
two categories were compared with a two-tailed unpaired t-test.
Non-normally distributed continuous variables are presented as
median and interquartile range. Differences of non-parametric
Figure 1. Boxplots showing MIF-levels according to acuity of CAD compared with healthy volunteers.
doi:10.1371/journal.pone.0038376.g001
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U-Test. An univariate analysis of covariance (ANCOVA) was used
to estimate the effects of different factors on MIF expression. Main
effects of relevant demographic factors and factors with influence
on MIF expression in univariate analysis were entered into the
model. All analyses were two-sided and a p-value ,0.05 was
considered statistically significant. Statistical analysis was per-
formed with SPSS, Version 15 for Windows (SPSS, Inc., Chicago,
IL).
Results
Study Cohort and Association of MIF-levels with
Demographic Factors
Baseline demographics of the whole study cohort are shown and
stratified according to levels of MIF under and beyond the median
in table 1. Patients with high MIF levels were in general older, had
more often arterial hypertension, hyperlipidemia, were more often
treated with ASA, clopidogrel, statins and AT1-inhibitors and had
a more preserved left-ventricular function compared to patients
with low MIF-levels (#1.96 ng/mL). Moreover, patients with high
MIF levels showed significantly higher numbers of monocytes in
the peripheral blood (p=0.047).
Patients with ACS had significant higher levels of MIF
compared to patients with stable CAD and healthy volunteers
(median 2.85 ng/ml, IQR 3.52 versus median 1.22 ng/ml, IQR
2.99, versus median 0.1, IQR 0.09, p,0.001, figure 1).
Univariate Analysis of Covariance for MIF-levels and
Possible Confounders for ACS
Baseline MIF-levels were independently associated with ACS in
unvariate analysis of covariance (F-value 11.96, p,0.001) after
inclusion of relevant variables in univariate analysis. Additionally,
renal function correlated with MIF plasma levels, decreased
glomerular filtration rate (F-value 23.35, p=0.004) was indepen-
dently associated with low MIF-levels. Arterial hypertension on the
other hand was independently associated with higher MIF-levels
(table 2).
Correlation of MIF with Inflammatory Markers and TnI
Release
Patients with a higher amount of MIF showed significantly
increased levels of CRP and IL-6, and trendwise increased levels of
RANTES and MCP-1 (figure 2).
Table 1. Baseline characteristics of the studied patients stratified according to median of MIF levels.
Characteristics Total,
Low to moderate MIF
(#1.96 ng/mL)
High MIF
(.1.96 ng/mL) p-value
n=286 n=143 n=143
Age * 67.9613.0 65.3614.0 70.4611.5 ,0.001
Female gender 84 (29.4) 38 (26.8) 46 (32.4) 0.298
Glomerular Filtration Rate (MDRD, mL/min/1.73 m
2)* 35.2617.4 31.2614.0 39.0619.5 ,0.001
Leucocyte count (10
3/ml) 8.763.1 8.463.2 8.863.1 0.136
Monocyte count (% of leucocytes) 5.060.2 4.563.6 5.363.1 0.047
Cardiovascular risk factors – no (%)
Arterial Hypertension 221 (77.3) 94 (66.2) 125 (88.0) ,0.001
Diabetes 88 (30.8) 36 (25.4) 50 (35.2) 0.071
Hyperlipidemia 168 (58.7) 71 (50.0) 95 (66.9) 0.004
Tobacco use 105 (36.7) 48 (33.8) 57 (40.1) 0.269
Acute coronary syndrome 119 (41.9) 44 (31.0) 75 (52.8) ,0.001
LV-Function
Slightly reduced (EF,55%) 70 (24.5) 24 (16.9) 45 (31.7) 0.002
Moderately reduced (EF 35–45%) 55 (19.2) 31 (21.8) 24 (16.9)
Severely reduced (EF,35%) 49 (17.1) 34 (23.9) 15 (10.6)
Comedication – no (%)
ASA 189 (66.1) 84 (59.2) 103 (72.5) 0.017
Clopidogrel 87 (30.4) 35 (24.6) 51 (64.1) 0.039
Phenprocoumon 20 (7.0) 9 (6.3) 11 (7.7) 0.643
ACE-Inhibitors 177 (61.9) 93 (65.5) 83 (58.8) 0.222
AT1-Blockers 48 (16.8) 35 (24.6) 13 (9.2) ,0.001
Beta-Blockers 214 (74.8) 106 (74.6) 107 (75.4) 0.891
Diuretics 153 (53.5) 80 (56.3) 71 (50.0) 0.285
Statins 140 (49.0) 59 (41.5) 80 (56.3) 0.013
*mean value 6 standard deviation.
{Hyperlipidemia was defined as triglycerides $175 mg/dl and/or LDL-cholesterol$100 mg/dl and/or taking any of lipid lowering drugs.
ASA: aspirin.
doi:10.1371/journal.pone.0038376.t001
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Coefficients mean 95% Confidence Interval F Mean Square Sig
Lower Bound Upper Bound
Age 0.925 2.591 0.337
Gender Male 2.29 1.87 2.70 1.49 4.18 0.223
female 2.59 2.06 3.12
Arterial Hypertension No 2.16 1.58 2.75 3.98 11.21 0.047
Yes 2.71 2.31 3.11
Acute coronary syndrome 2.81 2.31 3.31 11.21 31.59 ,0.001
Stable CAD 2.06 1.64 2.48
Diabetes No 2.47 2.07 2.88 0.13 0.37 0.72
Yes 2.40 1.87 2.93
Hyperlipidemia: No 2.21 1.73 2.69 3.77 10.62 0.05
Yes 2.67 2.20 3.13
Renal function (MDRD, mL/
min/1.73 m
2)
6.55 18.45 0.01
Reduced LV- function No 2.36 1.86 2.87 1.95 0.70 0.41
Yes 2.67 2.24 3.11
AT1-Blockers No 2.41 2.06 2.76 0.03 0.07 0.87
Yes 2.46 1.83 3.10
Statins No 2.35 1.87 2.83 0.51 1.43 0.48
Yes 2.52 2.04 3.01
ASA No 2.46 1.92 2.99 0.026 0.07 0.87
Yes 2.41 1.98 2.85
Clopidogrel No 2.39 1.99 2.80 0.04 0.11 0.84
Yes 2.48 1.93 3.04
{Hyperlipidemia was defined as triglycerides $175 mg/dl and/or LDL-cholesterol$100 mg/dl and/or taking any of lipid lowering drugs.
ASA: aspirin.
doi:10.1371/journal.pone.0038376.t002
Figure 2. Association of inflammatory markers IL-6, RANTES, MCP-1 and CRP with MIF levels in the study cohort.
doi:10.1371/journal.pone.0038376.g002
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correlated with MIF-expression in the patient cohort (spearman
rank coefficient: 0.31, p,0.001, figure 3).
High Plasma Levels of MIF are Associated with the
Presence of Plaque Ruptures in ACS Patients
Patients with ACS were also analyzed regarding the presence of
plaque rupture as verified by coronary angiography. Remarkably,
Figure 3. Correlation of the extent of maximum TnI release after PCI in the study cohort.
doi:10.1371/journal.pone.0038376.g003
Figure 4. Patients with ACS due to plaque rupture showed higher plasma levels of MIF than patients with flow limiting stenotic
lesions in coronary angiography.
doi:10.1371/journal.pone.0038376.g004
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lesion due to vulnerable plaques showed significantly higher
plasma levels of MIF compared to patients with ACS caused by
flow limiting stenotic lesions (p=0.002, figure 4). In ROC analysis,
we identified a cut off-value of 1.22 ng/mL with a sensitivity of
82% and a specifity of 56% and of 1.7 ng/mL with a sensitivity of
67% and a specifitiy of 62% for the diagnosis of ACS compared to
patients with stable CAD and healthy controls. For the diagnosis
of plaque rupture in ACS patients we found a high specifity (92%)
for MIF levels .5.1 ng/mL.
Discussion
In the present study we demonstrate that the expression of MIF
is significantly enhanced in ACS at an early phase during the
event. This effect was independent from other risk factors that
were reported to influence the incidence and prognosis of ACS.
There is growing evidence that recruitment and migration of
inflammatory cells into the vessel wall lead to promotion of
atherosclerosis and support the development of unstable athero-
sclerotic lesions. The different phases of monocyte and macro-
phage recruitment, adhesion and transmigration are regulated by
specifically acting chemokines [11,12]. MIF has previously been
decribed in many other proinflammatory diseases such as arthritis
[13], septic shock [14], colitis and hypersensitivity syndrome [15].
MIF is a chemokine-like protein and therefore takes over many
chemokine like functions regarding the recruitment and chemo-
taxis of inflammatory cells and the evolvement of atherosclerotic
lesions. Association of MIF with extensive lesion development was
previously described in animal models of hypercholesterolemic
rabbits [16]. In clinical setting, there are only few reports
investigating the association of MIF-expression with markers of
plaque instability. The formation of vulnerable plaques in
coronary arteries is a critical stage of the atherosclerotic disease
with a high risk for acute myocardial infarction. Therefore, it is
crucial to understand its mechanisms. Vulnerable plaques are
characterized through high inflammatory activity indexed by a
high content of inflammatory cells such as monocytes/macro-
phages and various chemokines that critically contribute to plaque
rupture. In a Chinese population, a significant correlation between
MIF and activator protein-1 (AP-1) and MMP-9 and -2
concentrations was found [17].
We could show that high plasma levels of MIF are found in
ACS patients with ‘‘culprit’’ lesions followed by plaque rupture.
These results may suggest that MIF plays an important role in
plaque development and stability. Therefore, MIF may serve as a
marker of early ACS and of plaque instability.
We also found an association of higher MIF-levels with the
expression of established inflammatory markers. Amplification of
the inflammatory response is critical for the development of acute
coronary events. Additionally, inflammatory response is associated
with the outcome after PCI. Previous studies demonstrated an
association between the degree of inflammatory response mea-
sured by inflammatory markers, platelet hyperactivity and
outcome in PCI-patients. We further investigated the role of
MIF on cardiac necrosis marker release. Thus, we found a relevant
correlation of initial MIF-levels and subsequent maximum
amounts of TnI after PCI.
We are aware that the present study is barely hypothesis
generating and has its limitations. First of all, it is a cross-sectional
study and we did not perform repeated measurements to
investigate the stability and time course of MIF plasma concen-
tration. Secondly, we neither investigated markers of plaque
instability, nor the prognostic impact of MIF-levels.
In conclusion, the present data underscore the necessity to
further characterize the role of MIF for risk marker analysis and its
prognostic role in patients with symptomatic CAD undergoing
PCI. We demonstrate that there is a highly significant and
independent association of increased plasma amounts of MIF in
ACS. Additionally, we show that MIF expression correlates with
inflammatory response and the extent of cardiac necrosis markers.
This finding is of utmost clinical importance as a linkage of
inflammatory response, platelet function and adverse cardiovas-
cular outcome including stent thrombosis has been described
previously [18]. Thus, multimodal strategies are supported to
addresss the question, if anti-inflammatory and plaque-stabilizing
approaches can lead to improved prognosis in patients with
symptomatic CAD undergoing PCI [19]. Hence, identification of
MIF expression can support risk-stratification in multimarker
approaches for ACS. Effects of MIF-modulation on cardiovascular
outcome should be investigated in the future. Thus, specific
molecules targeting MIF have been recently described [20] and
might move into the focus of CAD treatment in the future.
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